Skip to content
Business Times – Lifestyle
Author:
IGI, Inc.
Ichnos Glenmark Innovation (IGI) to Present Updated Clinical Data for ISB 2001 (ABBV-2001) in Relapsed/Refractory Multiple Myeloma at 68th ASH Annual Meeting
November 4, 2026
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
June 23, 2026
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
May 20, 2026